Optimising low-dose methotrexate for rheumatoid arthritis-A review

Catherine J. Lucas, Simon B. Dimmitt, Jennifer H. Martin

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Methotrexate at low doses (5-25 mg/week) is first-line therapy for rheumatoid arthritis. However, there is inter- and intrapatient variability in response, with contribution of variability in concentrations of active polyglutamate metabolites, associated with clinical efficacy and toxicity. Prescribing remains heterogeneous across population groups, disease states and regimens. This review examines current knowledge of dose-response of oral methotrexate in the setting of rheumatoid arthritis, and how this could help inform dosage regimens.

Original languageEnglish
Number of pages7
JournalBritish Journal of Clinical Pharmacology
DOIs
Publication statusE-pub ahead of print - 9 Aug 2019

Cite this

@article{75cbb38fcef94e01aa9ac2e9c97f4cc0,
title = "Optimising low-dose methotrexate for rheumatoid arthritis-A review",
abstract = "Methotrexate at low doses (5-25 mg/week) is first-line therapy for rheumatoid arthritis. However, there is inter- and intrapatient variability in response, with contribution of variability in concentrations of active polyglutamate metabolites, associated with clinical efficacy and toxicity. Prescribing remains heterogeneous across population groups, disease states and regimens. This review examines current knowledge of dose-response of oral methotrexate in the setting of rheumatoid arthritis, and how this could help inform dosage regimens.",
keywords = "clinical pharmacology, methotrexate, pharmacodynamics, pharmacokinetics, prescribing, rheumatoid arthritis, MODIFYING ANTIRHEUMATIC DRUGS, PULSE METHOTREXATE, SUBCUTANEOUS METHOTREXATE, ORAL METHOTREXATE, DISEASE-ACTIVITY, DOUBLE-BLIND, RISK-FACTORS, POLYGLUTAMATE CONCENTRATIONS, COMBINATION THERAPY, AMERICAN-COLLEGE",
author = "Lucas, {Catherine J.} and Dimmitt, {Simon B.} and Martin, {Jennifer H.}",
year = "2019",
month = "8",
day = "9",
doi = "10.1111/bcp.14057",
language = "English",
journal = "British Journal Clinical Pharmacology",
issn = "0306-5251",
publisher = "John Wiley & Sons",

}

Optimising low-dose methotrexate for rheumatoid arthritis-A review. / Lucas, Catherine J.; Dimmitt, Simon B.; Martin, Jennifer H.

In: British Journal of Clinical Pharmacology, 09.08.2019.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Optimising low-dose methotrexate for rheumatoid arthritis-A review

AU - Lucas, Catherine J.

AU - Dimmitt, Simon B.

AU - Martin, Jennifer H.

PY - 2019/8/9

Y1 - 2019/8/9

N2 - Methotrexate at low doses (5-25 mg/week) is first-line therapy for rheumatoid arthritis. However, there is inter- and intrapatient variability in response, with contribution of variability in concentrations of active polyglutamate metabolites, associated with clinical efficacy and toxicity. Prescribing remains heterogeneous across population groups, disease states and regimens. This review examines current knowledge of dose-response of oral methotrexate in the setting of rheumatoid arthritis, and how this could help inform dosage regimens.

AB - Methotrexate at low doses (5-25 mg/week) is first-line therapy for rheumatoid arthritis. However, there is inter- and intrapatient variability in response, with contribution of variability in concentrations of active polyglutamate metabolites, associated with clinical efficacy and toxicity. Prescribing remains heterogeneous across population groups, disease states and regimens. This review examines current knowledge of dose-response of oral methotrexate in the setting of rheumatoid arthritis, and how this could help inform dosage regimens.

KW - clinical pharmacology

KW - methotrexate

KW - pharmacodynamics

KW - pharmacokinetics

KW - prescribing

KW - rheumatoid arthritis

KW - MODIFYING ANTIRHEUMATIC DRUGS

KW - PULSE METHOTREXATE

KW - SUBCUTANEOUS METHOTREXATE

KW - ORAL METHOTREXATE

KW - DISEASE-ACTIVITY

KW - DOUBLE-BLIND

KW - RISK-FACTORS

KW - POLYGLUTAMATE CONCENTRATIONS

KW - COMBINATION THERAPY

KW - AMERICAN-COLLEGE

U2 - 10.1111/bcp.14057

DO - 10.1111/bcp.14057

M3 - Review article

JO - British Journal Clinical Pharmacology

JF - British Journal Clinical Pharmacology

SN - 0306-5251

ER -